- Home
- CCD vs CSTL Comparison
CCD vs CSTL Comparison
Compare CCD & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCD | CSTL |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.7M | 661.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CCD | CSTL |
|---|---|---|
| Price | $21.35 | $39.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $40.67 |
| AVG Volume (30 Days) | 96.1K | ★ 435.5K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $343,530,000.00 |
| Revenue This Year | N/A | $1.69 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $16.93 | $14.59 |
| 52 Week High | $24.68 | $40.61 |
Technical Indicators
Market Signals| Indicator | CCD | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 53.17 | 69.36 |
| Support Level | $20.55 | $37.76 |
| Resistance Level | $21.80 | $40.23 |
| Average True Range (ATR) | 0.33 | 1.26 |
| MACD | -0.03 | -0.36 |
| Stochastic Oscillator | 63.98 | 70.33 |
Price Performance
Historical ComparisonAbout CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.